Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.83 |
| ▸ | NPC1 | O15118 | 5/20 | 0.83 |
| ▸ | RAB9A | P51151 | 5/20 | 0.83 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465149 | 0.91 | ALDH1A1 (1.00) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL31237652 | 0.90 | ALDH1A1 (0.82) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL6534320 | 0.88 | HPGD (0.79) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2799908 | 0.86 | HPGD (0.76) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL13232473 | 0.85 | ALDH1A1 (1.00) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL28094944 | 0.85 | ALDH1A1 (0.73) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL31238209 | 0.84 | HPGD (0.72) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL6534639 | 0.84 | HPGD (1.00) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL29411859 | 0.84 | HPGD (1.00) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL15233667 | 0.82 | HPGD (0.69) | HPGDALDH1A1KDM4ESMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524740-B2 | Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives | TAIRX, INC. (TW) | 2013-09-03 | — | — | US | disclosed |
| US-20130102627-A1 | Acridines As Inhibitors Of Haspin And DYRK Kinases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| EP-1088818-B1 | Quinolin-4-yl derivatives | HOFFMANN LA ROCHE (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-6440995-B1 | NMDA-RECEPTOR SUBTYPE SELECTIVE BLOCKERS | HOFFMAN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102627-A1 | Acridines As Inhibitors Of Haspin And DYRK Kinases | HASPIN, MAP3K6, DAPK2 | HPGD 1984/4885ALDH1A1 3296/4885KDM4E 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.